BioMarin Pharmaceutical Inc. (BioMarin) develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company’s product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate).
BioMartin has been losing money and will lose in the coming years.
What is terribel is that the CEO has been selling its stocks more recently, and consistently ! read at
https://sportsperspectives.com/2017/01/05/biomarin-pharmaceutical-inc-bmrn-ceo-jean-jacques-bienaime-sells-8000-shares-of-stock/
Sell !